5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: A placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19)

Journal of Clinical Oncology

Volumn 24, Issue 21, 2006, Pages 3458-3464

  Wong, Rebecca K S ^a   Paul, Nancy ^b   Ding, Keyue ^b   Whitehead, Marlo ^b   Brundage, Michael ^b   Fyles, Anthony ^b   Wilke, Derek ^b   Nabid, Abdenour ^b   Fortin, Andre ^b   Wilson, Don ^b   McKenzie, Michael ^b   Ackerman, Ida ^b   Souhami, Luis ^b   Chabot, Pierre ^b   Pater, Joseph ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ONDANSETRON; PLACEBO; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; ANTIEMETIC AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

ADULT; APPETITE; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INDUCED EMESIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH ULCER; CANADA; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; RADIOTHERAPY; TREATMENT OUTCOME; VOMITING;

ANTIEMETICS; CANADA; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; QUALITY OF LIFE; RADIOTHERAPY; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 33746855165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4685     Document Type: Article

References (31)

1. Court-Brown W: Symptomatic disturbance of the single therapeutic dose of X-rays. BMJ 1:802-804, 1953
2. Danjoux C, Rider W, Fitzpatrick P: The acute radiation syndrome. Clin Radiol 30:581-584, 1979
3. Sagar S: The current role of anti-emetic drug in oncology: A recent revolution in patient symptom control. Cancer Treatment Rev 18:95-135, 1991
4. Young R: Mechanisms and treatment of radiation induced nausea and vomiting, in Davis C, Lake-Bahrr G, Grahame-Smith D (eds): Nausea and Vomiting: Mechanisms and treatment. Berlin Heidelberg, Germany, Springer-Verlag, 1986
5. Tramer MR, Reynolds DJ, Stoner NS, et al: Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: A quantitative systematic review. Eur J Cancer 34:1836-1844, 1998
6. Bey P, Wilkinson PM, Resbeut M, et al: A double-blind, placebo-controlled trial of IV dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 4:378-383, 1996
7. Spitzer TR, Bryson JC, Cirenza E, et al: Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 12:2432-2438, 1994
8. Franzen L, Nyman J, Hagberg H, et al: A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 7:587-592, 1996
9. Khoo VS, Rainford K, Horwich A, et al: The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: A randomized pilot study. Clin Oncol (Royal College of Radiologists) 9:252-257, 1997
10. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment, LeBourgeois JP, McKenna CJ, Coster B, et al: Efficacy of an ondansetron orally disintegrating tablet: A novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Clin Oncol (Royal College of Radiologists) 11:340-347, 1999
11. Priestman TJ, Roberts JT, Lucraft H, et al: Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (Royal College of Radiologists) 2:71-75, 1990
12. Sykes AJ, Kiltie AE, Stewart AL: Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: A prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 5:500-503, 1997
13. Priestman TJ, Roberts JT, Upadhyaya BK: A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (Royal College of Radiologists) 5:358-363, 1993
14. Prentice HG, Cunningham S, Gandhi L, et al: Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15:445-448, 1995
15. Kirkbride P, Bezjak A, Pater J, et al: Dexamethasone for the prophylaxis of radiation-induced emesis: A National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 18:1960-1966, 2000
16. EORTC Quality of Life Group: European Organisation for Research in Cancer Quality of Life. http://www.eortc.be/home/qol/
17. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005
18. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 41:582-592, 2003
19. Wyrwich KW, Fihn SD, Tierney WM, et al: Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: An expert consensus panel report. J Gen Intern Med 18:196-202, 2003
20. Norman GR, Sridhar FG, Guyatt GH, et al: Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 39:1039-1047, 2001
21. Zanolla L, Zardini P: Selection of endpoints for heart failure clinical trials. European Journal of Heart Failure 5:717-723, 2003
22. Hauptman PJ: Measurement of end points in heart failure trials: Jousting at windmills? Mt Sinai J Med 71:298-304, 2004
23. Legro RS, Myers E: Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum Reprod 19:1697-1704, 2004
24. Breitfeld PP: Assessing the overall impact of therapy: It's not so simple. J Pediatr Hematol Oncol 24:518-520, 2002
25. Twisk J, Proper K: Evaluation of the results of a randomized controlled trial: How to define changes between baseline and follow-up. J Clin Epidemiol 57:223-228, 2004
26. Maranzano E, Bellavita R, DeAngelis V, et al: Double-blind randomized clinical trial comparing prophylaxis vs. rescue treatment in patients undergoing fractionated upper abdomen radiotherapy, ESTRO. Amsterdam, the Netherlands, Elsevier, 2004, pp S386
27. ASHP: Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 56:729-764, 1999
28. NCCN: NCCN antiemesis practice guidelines. Oncology (Huntington) 11:57-89, 1997
29. Anonymous: Prevention of chemotherapy-and radiotherapy-induced emesis: Results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) 811-819, 1998
30. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. [erratum appears in J Clin Oncol 17:3860, 1999]. J Clin Oncol 17:2971-2994, 1999
31. Feyer P, Maranzano E, Molassiotis A, et al: Radiotherapy-induced nausea and vomiting (RINV): Antiemetic guidelines. Support Care Cancer 13:122-128, 2005